Funded by private investors and governments, cancer tests of blood and urine are coming to market.
How much does it cost to bring to market a diagnostic test that’s able to measure cancer without a tissue biopsy?
In the case of Trovagene, almost $100 million.
That’s the cumulative loss, or expense including salaries, R&D, and office space, the money-losing San Diego biotechnology outfit has run up since 1999, when it set out to test for cancer from a cup of urine. Just like recently developed cancer blood tests, the diagnostic the company started offering in May searches for telltale scraps of tumor DNA released by dying cancer cells. The amount of tumor DNA that ends up in urine is a readout, the company says, of whether a tumor has been destroyed or is still growing.
Wall Street analysts expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The idea of such liquid biopsies has leapt to prominence in just the last year. Cancer researchers now expect that the tests will offer a noninvasive way to monitor cancer, find the genetic mutations driving a tumor, or even diagnose it early, before symptoms start. It’s an innovation so big that Wall Street analysts at JP Morgan expect demand for liquid biopsies to rocket toward $20 billion a year within five years, from about $100 million today.
The first DNA blood test for cancer in the United States was commercialized in 2014 by Guardant Health, a venture-backed California company, and tests to spot cancer DNA in blood, urine, or spinal fluid are now in development by a growing number of companies but remain a risky bet for investors.
One pioneering researcher, Dennis Lo, is now tracking more than 20,000 people in Hong Kong to see whether blood screening can catch liver cancer early. Some of his early and ongoing work was paid for by a $1 million grant from the Kadoorie Charitable Foundation, the charity of Hong Kong billionaire Michael Kadoorie, and he later won a $4.25 million award from the Hong Kong government. “It took us about 10 years to convince people to fund us,” he says. Lo says he recently cofounded a company called Cirina to develop blood tests, and he expects initial financing of $12 million from investors.
Investors in the new tests could be disappointed, because while developing a new diagnostic can cost as much as creating a new drug, it’s notoriously hard to make any money off diagnostic tests.
The Latest on: Liquid Biopsy
via Google News
The Latest on: Liquid Biopsy
- Top Picks 2020- Guardant Health GHon January 10, 2020 at 2:43 pm
For investors looking for a stock that has a real shot of doubling in value during 2020, they should consider purchase of Guardant Health Inc. (GH), notes growth and income expert Bryan Perry, editor ...
- Here's Why Guardant Health Shares Rose 107.9% in 2019on January 10, 2020 at 10:53 am
Shares of Guardant Health (NASDAQ:GH) rose nearly 108% last year, according to data provided by S&P Global Market Intelligence. In its first full year on the market, the liquid biopsy specialist ...
- OncoCyte Meets An Important Milestone With The Completion Of CLIA Validation Of DetermaDxon January 10, 2020 at 5:54 am
For those who want to know more about DetermaDx you can read my previously article:"OncoCyte: Promising Future In The Field Of Liquid Biopsy Tests" This important milestone was expected, after several ...
- OncoCell MDx, Now Immunis.AI, to Present at Biotech Showcaseon January 9, 2020 at 5:30 am
ROYAL OAK, Mich.--(BUSINESS WIRE)--OncoCell MDx, a privately held immunogenomics company with a patented liquid biopsy platform, today announced it has changed its name to Immunis.AI. The name was ...
- Global Breast Cancer Liquid Biopsy Testing Devices Market 2020-2024 | Evolving Opportunities with Biocept Inc. and Genomic Health Inc. | Technavioon January 9, 2020 at 5:30 am
LONDON--(Business Wire)--The global breast cancer liquid biopsy testing devices market is poised to grow by USD 479.83 million during 2020-2024 at a CAGR of almost 24% during the forecast period.
- Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsieson January 8, 2020 at 12:52 pm
R. Steven Paulson, MD, physician, Texas Oncology, discusses the utility of liquid biopsies versus tissue biopsies. Although tissue biopsy remains the gold standard in oncology, there may not be enough ...
- Eurofins Expands Kidney Transplant Diagnostics Offering Through Viracor TRAC(TM)on January 8, 2020 at 10:59 am
physicians and organ procurement organizations the most comprehensive transplant testing menu in the U.S. TRAC is a non-invasive liquid biopsy with similar performance characteristics to other ...
- Personal Genome Diagnostics, Mayo Clinic Partner to Enhance Patient Care in Oncologyon January 8, 2020 at 10:16 am
Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications. – The shared vision and overall goal ...
- Personal Genome Diagnostics and Mayo Clinic Enter Strategic Collaboration to Enhance Patient Care in Oncologyon January 8, 2020 at 4:00 am
Together, PGDx and Mayo Clinic will focus on technology optimization and clinical utility studies for liquid biopsy and tissue-based genomic applications. The two organizations have a shared vision ...
- OncoCyte Announces Successful Completion of CLIA Validation Study of DetermaDx™on January 7, 2020 at 5:08 am
IRVINE, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel tests for the early diagnosis and management of lung cancer, today announced the ...
via Bing News